The Academic partnerships are part of a new program called 'in silico' program:
Company Press Release
Incyte Pharmaceuticals Announces Academic Partnerships to
Streamline Drug Discovery
"In Silico Partnership Program" Provides Academic Investigators With Leading Genomics Technologies to Study
Disease on Molecular Level
PALO ALTO, Calif.--(BW HealthWire)--Sept. 20, 1999-- Incyte Pharmaceuticals, Inc. (Nasdaq:INCY - news), a leading provider of genomics technologies, today announced the creation of its ''In Silico Partnership Program.''
The new initiative expands access to Incyte's proprietary gene sequences for leading academic investigators studying the molecular basis of disease.
In Silico Partnerships will focus on gene function, gene expression and genetic analyses of complex diseases, including cardiovascular disease and
cancer. Researchers will gain access to Incyte's information, software and reagents including proprietary gene sequences from Incyte's LifeSeq® Gold
database, which contains information representing more than 90 percent of the expressed human genes, 50,000 of which are not currently available in
the public domain. Traditional research has centered on examining genes one by one. Incyte's products enable investigators to study thousands of genes
simultaneously, decreasing the time required to complete the research.
''This is an incredible opportunity for us to work together with the academic community on enhancing the future of health care,'' said Randy Scott,
president and chief scientific officer of Incyte. ''This collaborative program is the first step in making Incyte products and services broadly accessible to
the academic community. We envision this initiative having an amazingly positive impact on future research.''
Earlier this month, Incyte announced its alliance with the Huntsman Cancer Institute on the genetic study of colon cancer. Huntsman will use Incyte's
state-of-the art microarray technology as well as the LifeSeq Gold® database. In exchange, Incyte will have access to high-quality tissue and tumor
samples as well as research findings from Huntsman's colon cancer program.
''We are eager to join forces with academic experts in furthering the genetic study of other cancers and other diseases. The collaboration with
Huntsman is just the first of many to come,'' Scott said. ''We see a huge benefit in creating similar relationships with researchers throughout the
country.''
Incyte
Incyte Pharmaceuticals, Inc. is a leading provider of integrated platforms of genomic technologies designed to aid in the understanding of the molecular
basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services,
related reagents and services.
These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene
discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For
more information, contact Incyte at insilicopartners@incyte.com or visit Incyte's Web site at www.incyte.com.
Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the
''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports,
including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1999. Incyte disclaims any intent or obligation to update these
forward-looking statements.
|
